Modality
ADC
MOA
FGFRi
Target
PCSK9
Pathway
DDR
Hemophilia AEndometrial Ca
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Nov 2029
Phase 1Current
NCT07268292
1,217 pts·Hemophilia A
2025-03→2029-11·Recruiting
1,217 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-11-203.6y awayInterim· Hemophilia A
Trial Timeline
Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2029-11-20 · 3.6y away
Hemophilia A
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07268292 | Phase 1 | Hemophilia A | Recruiting | 1217 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Talatapinarof | Samsung Biologics | Phase 1/2 | PCSK9 |